Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (49)
Lama N. Hamadeh, Lama Farhat, Lamia Hilal, Hazem Assi, Fadi Nasr, Georges Chahine, Joseph Kattan, Fadi Farhat, Hampig Kourie, Georges El Hachem, Marwan Ghosn, Nagi El Saghir, Nabil Chamseddine, Antoine Finianos, Hady Ghanem, Ahmad Younes, Dany Abi Gerges, Sally Temraz, Mohammad Haidar, Therese Nabhan, Ali Chamseddine, Arafat Tfayli, Ghazi Zaatari & Rami Mahfouz. (2023) Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon. Gene 871, pages 147433.
Crossref
Crossref
Howard W. Bruckner, Sant P. Chawla, Nadezhda Omelchenko, Don A. Brigham & Erlinda M. Gordon. (2023) Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast. Frontiers in Molecular Medicine 3.
Crossref
Crossref
Alexandre Bertucci, François Bertucci & Anthony Gonçalves. (2023) Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. Cancers 15:5, pages 1416.
Crossref
Crossref
Yeqin Yuan, Huizhi Long, Ziwei Zhou, Yuting Fu & Binyuan Jiang. (2023) PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Biomolecules 13:1, pages 93.
Crossref
Crossref
Manuel Gámez-Chiachio, David Sarrió & Gema Moreno-Bueno. (2022) Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers 14:18, pages 4543.
Crossref
Crossref
Seop Lee, Min-Soo Kim, Jong-Woo Jeong, Jung-woo Chae, Tae-Sung Koo, Han-Joo Maeng, Suk-Jae Chung, Kyeong-Ryoon Lee & Yoon-Jee Chae. (2022) Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study. Journal of Analytical Science and Technology 13:1.
Crossref
Crossref
Nathalie Schneider, Ellen Reed, Faddy Kamel, Enrico Ferrari & Mikhail Soloviev. (2022) Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer. Genes 13:9, pages 1538.
Crossref
Crossref
Elif Ulu, İlhan Yaylım, Soykan Arıkan & Canan Cacına. (2022)
The evaluation of
PIK3CA
gene variation and serum PI3K level in breast cancer risk and prognosis in Turkish population
. Turkish Journal of Biochemistry 47:3, pages 317-324.
Crossref
Crossref
. (2022) Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer. Cancer Innovation 1:1, pages 25-54.
Crossref
Crossref
Aglaia Skolariki, Jamie D’Costa, Martin Little & Simon Lord. (2022) Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-tumor Therapy, pages 172-199.
Crossref
Crossref
Katelyn N Seale & Katherine H R Tkaczuk. (2022) Circulating Biomarkers in Breast Cancer. Clinical Breast Cancer 22:3, pages e319-e331.
Crossref
Crossref
Sahar Mafi, Behzad Mansoori, Shahram Taeb, Hossein Sadeghi, Reza Abbasi, William C. Cho & Davoud Rostamzadeh. (2022) mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. Frontiers in Immunology 12.
Crossref
Crossref
Alejandra Ortiz-González, Pedro Pablo González-Pérez, Maura Cárdenas-García & María Guadalupe Hernández-Linares. (2022)
In silico
Prediction on the PI3K/AKT/mTOR Pathway of the Antiproliferative Effect of
O. joconostle
in Breast Cancer Models
. Cancer Informatics 21, pages 117693512210870.
Crossref
Crossref
Violette Allouchery, Anne Perdrix, Céline Calbrix, Anca Berghian, Justine Lequesne, Maxime Fontanilles, Marianne Leheurteur, Pascaline Etancelin, Nasrin Sarafan-Vasseur, Frédéric Di Fiore & Florian Clatot. (2021) Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients. Scientific Reports 11:1.
Crossref
Crossref
Denghui Liu, Chi Xu, Wenjun He, Zhimeng Xu, Wenqi Fu, Lei Zhang, Jie Yang, Zhihao Wang, Bing Liu, Guangdun Peng, Dali Han, Xiaolong Bai & Nan Qiao. (2021) AutoGenome: An AutoML tool for genomic research. Artificial Intelligence in the Life Sciences 1, pages 100017.
Crossref
Crossref
Mohamad Abufaied, Unwam Jumbo, Adala Alqalalwah & Mohammad Khair Hamad. (2021) Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer. Cureus.
Crossref
Crossref
Sebanti Ganguly, Itika Arora & Trygve O. Tollefsbol. (2021) Impact of Stilbenes as Epigenetic Modulators of Breast Cancer Risk and Associated Biomarkers. International Journal of Molecular Sciences 22:18, pages 10033.
Crossref
Crossref
Duna H. Barakeh, Rasha Aljelaify, Yara Bashawri, Amal Almutairi, Fatimah Alqubaishi, Mohammed Alnamnakani, Latifa Almubarak, Abdulrahman Al Naeem, Fatema Almushawah, May Alrashed & Malak Abedalthagafi. (2021) Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients. Oncotarget 12:7, pages 686-697.
Crossref
Crossref
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie & Ceshi Chen. (2021) Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Przemysław Kołodziej, Marcin Nicoś, Paweł A. Krawczyk, Jacek Bogucki, Agnieszka Karczmarczyk, Daniel Zalewski, Tomasz Kubrak, Elżbieta Kołodziej, Anna Makuch-Kocka, Barbara Madej-Czerwonka, Bartosz J. Płachno, Janusz Kocki & Anna Bogucka-Kocka. (2021) The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer—A Preliminary Study. International Journal of Molecular Sciences 22:4, pages 2061.
Crossref
Crossref
José Alberto Carlos-Escalante, Juan Pablo Calderón & Talia Wegman-Ostrosky. 2021. Principles of Neuro-Oncology. Principles of Neuro-Oncology
43
73
.
Om Prakash, Fokhrul Hossain, Denise Danos, Adam Lassak, Richard Scribner & Lucio Miele. (2020) Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. Frontiers in Public Health 8.
Crossref
Crossref
Arunaksharan Narayanankutty. (2020) Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery 15:3, pages 188-199.
Crossref
Crossref
Mary Glorieux, Rüveyda Dok & Sandra Nuyts. (2020) The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Scientific Reports 10:1.
Crossref
Crossref
Petr Lapcik, Anna Pospisilova, Lucia Janacova, Peter Grell, Pavel Fabian & Pavel Bouchal. (2020) How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?. Cancers 12:9, pages 2638.
Crossref
Crossref
Zhonghua Tao, Ting Li, Zhe Feng, Chang Liu, Yilin Shao, Mingyu Zhu, Chengcheng Gong, Biyun Wang, Jun Cao, Leipin Wang, Yiqun Du, Analyn Lizaso, Bing Li, Jian Zhang & Xichun Hu. (2020) Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. Frontiers in Oncology 10.
Crossref
Crossref
Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang & Lisa E. Davis. (2020) A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. International Journal of Breast Cancer 2020, pages 1-16.
Crossref
Crossref
Pamela R. Drullinsky & Sara A. Hurvitz. (2020) Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Research and Treatment 181:2, pages 233-248.
Crossref
Crossref
André Franken, Mahdi Rivandi, Liwen Yang, Bernadette Jäger, Natalia Krawczyk, Ellen Honisch, Dieter Niederacher, Tanja Fehm & Hans Neubauer. (2020) A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells. Applied Sciences 10:10, pages 3364.
Crossref
Crossref
Nirupama Devanathan, Sandra Jones, Gursimran Kaur & Ann C. Kimble-Hill. (2020) Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer. International Journal of Molecular Sciences 21:7, pages 2320.
Crossref
Crossref
Wandee Udomchaiprasertkul, Pravit Kitidumrongsook, Kanya Suphapeetiporn & Vorasuk Shotelersuk. (2019)
A somatic
PIK3CA
p.H1047L mutation in a Thai patient with isolated macrodactyly: a case report
. Asian Biomedicine 13:1, pages 33-36.
Crossref
Crossref
Kang-Hoon Lee, Hyeon-Ji Hwang, Hyun Ji Noh, Tae-Jin Shin & Je-Yoel Cho. (2019) Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers. Cancers 11:12, pages 2006.
Crossref
Crossref
D. L. Rotin, O. V. Paklina, I. O. Tin’kova & D. N. Grekov. (2019) MICROSATELLITE INSTABILITY AND GASTRIC CARCINOMA. REVIEW OF THELITERATURE. Russian Journal of Biotherapy 18:4, pages 17-24.
Crossref
Crossref
Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga & Teeru Bihani. (2019) Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Research 21:1.
Crossref
Crossref
Hossein Fallahi & Rasoul Godini. (2019) System-level responses to cisplatin in pro-apoptotic stages of breast cancer MCF-7 cell line. Computational Biology and Chemistry 83, pages 107155.
Crossref
Crossref
Michaela Reagan. 2019. Cancer. Cancer
53
74
.
Daniele Presti & Erica Quaquarini. (2019) The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers 11:9, pages 1242.
Crossref
Crossref
Hironobu Minami, Yutaka Fujiwara, Kei Muro, Masahiko Sato & Atsuko Moriya. (2019) Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers. Cancer Chemotherapy and Pharmacology 84:2, pages 337-343.
Crossref
Crossref
G. Weldon Gilcrease, David D. Stenehjem, Mark L. Wade, John Weis, Kimberly McGregor, Jonathan Whisenant, Kenneth M. Boucher, Kelli Thorne, Nicole Orgain, Ignacio Garrido-Laguna & Sunil Sharma. (2018) Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs 37:3, pages 482-489.
Crossref
Crossref
Marica Garziera, Rossana Roncato, Marcella Montico, Elena De Mattia, Sara Gagno, Elena Poletto, Simona Scalone, Vincenzo Canzonieri, Giorgio Giorda, Roberto Sorio, Erika Cecchin & Giuseppe Toffoli. (2019) New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Cells 8:6, pages 584.
Crossref
Crossref
Deli Hong, Andrew J. Fritz, Jonathan A. Gordon, Coralee E. Tye, Joseph R. Boyd, Kirsten M. Tracy, Seth E. Frietze, Frances E. Carr, Jeffrey A. Nickerson, Andre J. Van Wijnen, Anthony N. Imbalzano, Sayyed K. Zaidi, Jane B. Lian, Janet L. Stein & Gary S. Stein. (2018) RUNX1‐dependent mechanisms in biological control and dysregulation in cancer. Journal of Cellular Physiology 234:6, pages 8597-8609.
Crossref
Crossref
Xu Liang, Sophie Vacher, Anais Boulai, Virginie Bernard, Sylvain Baulande, Mylene Bohec, Ivan Bièche, Florence Lerebours & Céline Callens. (2018) Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Research 20:1.
Crossref
Crossref
Rekha Gyanchandani, Erik Kvam, Ryan Heller, Erin Finehout, Nicholas Smith, Karthik Kota, John R. Nelson, Weston Griffin, Shannon Puhalla, Adam M. Brufsky, Nancy E. Davidson & Adrian V. Lee. (2018) Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Scientific Reports 8:1.
Crossref
Crossref
Yulei Zhao, Tess Montminy, Taha Azad, Elizabeth Lightbody, Yawei Hao, Sandip SenGupta, Eric Asselin, Christopher Nicol & Xiaolong Yang. (2018) PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways. Molecular Cancer Research 16:6, pages 1046-1058.
Crossref
Crossref
Virginia Alvarez-Garcia, Clare Bartos, Ieva Keraite, Urmi Trivedi, Paul M. Brennan, Maïwenn Kersaudy-Kerhoas, Karim Gharbi, Olga Oikonomidou & Nicholas R. Leslie. (2018) A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Scientific Reports 8:1.
Crossref
Crossref
Rita Lampignano, Liwen Yang, Martin Neumann, André Franken, Tanja Fehm, Dieter Niederacher & Hans Neubauer. (2017) A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. International Journal of Molecular Sciences 18:9, pages 1885.
Crossref
Crossref
Jun Qian, Heidi Chen, Xiangming Ji, Rosana Eisenberg, A. Bapsi Chakravarthy, Ingrid A. Mayer & Pierre P. Massion. (2017) A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Scientific Reports 7:1.
Crossref
Crossref
Vassiliki Kotoula, Vasilios Karavasilis, Flora Zagouri, George Kouvatseas, Eleni Giannoulatou, Helen Gogas, Sotiris Lakis, George Pentheroudakis, Mattheos Bobos, Kyriaki Papadopoulou, Eleftheria Tsolaki, Dimitrios Pectasides, Georgios Lazaridis, Angelos Koutras, Gerasimos Aravantinos, Christos Christodoulou, Pavlos Papakostas, Christos Markopoulos, George Zografos, Christos Papandreou & George Fountzilas. (2016) Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment 158:2, pages 307-321.
Crossref
Crossref
Michael P. Lux, Peter A. Fasching, Michael G. Schrauder, Alexander Hein, Sebastian M. Jud, Claudia Rauh & Matthias W. Beckmann. (2016) The PI3K Pathway: Background and Treatment Approaches. Breast Care 11:6, pages 398-404.
Crossref
Crossref